Viking Therapeutics, Inc. (VKTX)
31.53
+0.73
(+2.37%)
USD |
NASDAQ |
May 27, 15:48
Viking Therapeutics Cash from Investing (Quarterly) : 54.19M for March 31, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Eli Lilly & Co. | -3.916B |
| Amgen, Inc. | -716.00M |
| Catalyst Pharmaceuticals, Inc. | -0.027M |
| Altimmune, Inc. | -3.69M |
| TG Therapeutics, Inc. | -9.864M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -113.98M |
| Cash from Financing (Quarterly) | 12.08M |
| Free Cash Flow | -340.33M |
| Free Cash Flow Per Share (Quarterly) | -0.9862 |
| Free Cash Flow to Equity (Quarterly) | -113.84M |
| Free Cash Flow to Firm (Quarterly) | -113.98M |
| Free Cash Flow Yield | -9.51% |